National Consensus Guideline for Treatment of Postpartum Haemorrhage

Aratohu Tūtohu ā-Motu mō te Tumahu Ikura Whakawhānau Pēpi

March 2022

Citation: Ministry of Health. 2022. *National Consensus Guideline for Treatment of Postpartum Haemorrhage | Aratohu Tūtohu ā-Motu mō te Tumahu Ikura Whakawhānau Pēpi*. Wellington: Ministry of Health.

Published in March 2022 by the Ministry of Health  
PO Box 5013, Wellington 6140, New Zealand

ISBN 978-1-99-110026-9 (online)  
HP 8061



This document is available at [health.govt.nz](http://www.health.govt.nz)

|  |  |
| --- | --- |
| **CCBY** | This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to: share ie, copy and redistribute the material in any medium or format; adapt ie, remix, transform and build upon the material. You must give appropriate credit, provide a link to the licence and indicate if changes were made. |

Contents

[Introduction 1](#_Toc98345402)

[Purpose 1](#_Toc98345403)

[Need for this consensus guideline 1](#_Toc98345404)

[Users of this consensus guideline 2](#_Toc98345405)

[Te Tiriti o Waitangi 2](#_Toc98345406)

[Equity 3](#_Toc98345407)

[Definition of PPH 5](#_Toc98345408)

[Summary of guidance 6](#_Toc98345409)

[Treating PPH 6](#_Toc98345410)

[Education 7](#_Toc98345411)

[Communications 8](#_Toc98345412)

[Medicines used to treat PPH 9](#_Toc98345413)

[Implementation and monitoring 11](#_Toc98345414)

[Further advice on Te Tiriti 12](#_Toc98345415)

[Cultural safety 12](#_Toc98345416)

[Development process 14](#_Toc98345417)

[Bibliography 15](#_Toc98345418)

[Measuring, assessing and arresting blood loss 15](#_Toc98345419)

[Minimising impact of blood loss and resuscitation 28](#_Toc98345420)

# Introduction

## Purpose

This *National Consensus Guideline for Treatment of Postpartum Haemorrhage* (consensus guideline) is an evidence-based summary of best practice for the safe and effective treatment of postpartum haemorrhage (PPH). It aims to:

* ensure that PPH is identified early, so that health practitioners take action to treat it as soon as possible
* support early, open and effective communication between health practitioners and the woman/person, their partner and whānau
* reduce morbidity and mortality associated with PPH
* give effect to Te Tiriti o Waitangi (Te Tiriti), including by meeting the interests and needs of tangata whenua.

The consensus guideline sits alongside other relevant clinical guidelines. It should be read together with [Ngā paerewa Health and disability services standard 8134:2021](https://www.health.govt.nz/our-work/regulation-health-and-disability-system/certification-health-care-services/services-standards/nga-paerewa-health-and-disability-services-standard)(*Ngā paerewa*), the *Guidelines* *for* *Consultation with Obstetric and Medical Services* and Health and Disability Commissioner (*Code of Health and Disability Services Consumer Rights*) Regulations 1996.

## Need for this consensus guideline

PPH is a significant cause of perinatal morbidity and accounts for a large proportion of admissions and extended postpartum inpatient hospital stays. This consensus guideline supports the development of a consistent and shared multidisciplinary understanding of PPH and its effective management to optimise care and outcomes for women/people who experience abnormal bleeding after giving birth.

This consensus guideline should underpin clinical judgement and decision-making to guide treatment. This includes:

* giving effect to our obligations under Te Tiriti principles, including meeting the needs and interests of Māori
* ensuring safe, effective and whānau-centred services that are equitable, efficient and timely
* ensuring nationally consistent advice is available to health practitioners.

Prevention of PPH and active management of the third stage of labour are outside of the scope of this guideline.

## Users of this consensus guideline

This consensus guideline is written for health practitioners involved in birth and postpartum care in Aotearoa New Zealand. Health practitioners should use it to support clinical judgement, knowledge and expertise and provide for a timely, consistent and effective approach to treating PPH. Recipients of care and their whānau can use this consensus guideline to understand the treatment of PPH.

## Te Tiriti o Waitangi

Health practitioners can demonstrate that they are giving effect to Te Tiriti by practically applying the principles as articulated by the courts and the Waitangi Tribunal.[[1]](#footnote-1) Applying the principles to maternity service delivery is vital to enabling Māori to express their mana[[2]](#footnote-2) and ensures they receive high-quality, culturally safe care and achieve equitable health outcomes. Using the principles to work effectively and respectfully with Māori requires maternity services and health practitioners to demonstrate the principles of Te Tiriti in their day-to-day practice with Māori.

The principles of Te Tiriti provide the framework for maternity providers and health practitioners providing maternity services to Māori. How these principles apply to maternity services is supported by *Ngā paerewa* and, in particular, [1.1 Pae ora healthy futures](https://www.health.govt.nz/our-work/regulation-health-and-disability-system/certification-health-care-services/services-standards/nga-paerewa-health-and-disability-services-standard/sector-guidance-nga-paerewa-health-and-disability-services-standard-nzs-81342021/part-1-our-rights).

The Waitangi Tribunal concluded that persistent health inequities that Māori experience were the consequence of the failure to apply the principles of Te Tiriti at structural, organisational and health practitioner levels of the health and disability sector. Giving effect to Te Tiriti requires health practitioners to know the principles of Te Tiriti and to capably apply these in partnership with Māori in their day-to-day maternity clinical practice.

For the health and disability sector, the [principles of Te Tirit](https://www.health.govt.nz/our-work/populations/maori-health/he-korowai-oranga/strengthening-he-korowai-oranga/treaty-waitangi-principles)i are as follows.

* **Tino rangatiratanga**: Health practitioners support the right of Māori to receive effective maternity care, conceptualising the decisions of the woman/person as a continuation of a much older, Māori collective-endorsed practice of self-determining one’s own health and wellbeing and that of the whānau.
* **Equity**: Health practitioners can contribute to equitable maternity health outcomes for Māori by ensuring that at a minimum maternity outcomes match those of other New Zealanders. Equitable maternity outcomes will be achieved when health practitioners implement the consensus guideline recommendations in ways that give effect to the principles of Te Tiriti, relevant professional competencies and *Ngā paerewa*.
* **Active protection**: Health practitioners share evidence-based information about maternity outcomes so that Māori can make decisions and prepare themselves to uphold their tikanga or cultural practice (for example, karakia, rongoā, support people). Health practitioners actively support Māori to make decisions that are best for them.
* **Options**: Health practitioners ensure Māori have maternity care that enables them to uphold their tikanga or cultural practice regardless of where birth takes place. Processes must complement a Māori person’s mana or inherent authority and dignity, support their tikanga or cultural practice and be culturally safe as defined by Māori.
* **Partnership**: Health practitioners work in partnership with Māori, including a person’s whānau if requested. A partnered approach to the process and decision-making ensures Māori can enact their rangatiratanga or self-determine their futures while exercising mana motuhake or authority over their bodies and reproductive health.

## Equity

In Aotearoa New Zealand, people have differences in health outcomes that are not only avoidable but unfair and unjust.[[3]](#footnote-3) Differences in the structural determinants of health and wellbeing – for example, disadvantages in income, employment, education and housing as well as multiple forms of discrimination – negatively impact people’s health but people have little control over these. Health inequities – like inequitable maternity outcomes – are not about people; instead they are the result of avoidable structural determinants in our communities.[[4]](#footnote-4) When health practitioners understand the structures that create inequitable maternity outcomes, they can use different approaches and resources to achieve equitable maternity outcomes.

Achieving equitable maternity outcomes for Māori happens when service providers and health practitioners:

* understand the structures that create Māori disadvantage
* are supported to implement the consensus guideline recommendations in ways that give effect to the principles of Te Tiriti, as well as meeting professional competencies and *Ngā paerewa*.

Other population groups in Aotearoa New Zealand also experience inequities that are unfair and unjust. Achieving equitable maternity outcomes for all happens when maternity service providers and health practitioners:

* understand the structures that create disadvantage for those groups
* are supported to implement the consensus guideline in ways that give effect to the rights of those groups while also meeting professional competencies and *Ngā paerewa*.

Last, health practitioners should be aware that many peoples in Aotearoa New Zealand conceptualise anatomy, pregnancy, gender, sexuality, reproduction, contraception and birth in different ways according to their worldviews. Therefore, health practitioners should use proven health literacy practices[[5]](#footnote-5) to communicate effectively with everyone using their services (for sector guidance, see *Ngā paerewa* Standard [1.4 E whakautetia ana ahau | I am treated with respect](https://www.health.govt.nz/our-work/regulation-health-and-disability-system/certification-health-care-services/services-standards/nga-paerewa-health-and-disability-services-standard/sector-guidance-nga-paerewa-health-and-disability-services-standard-nzs-81342021/part-1-our-rights) and criteria 1.4.2).

### Recommendations

* Health practitioners should be aware that different cultures and religions conceptualise anatomy, pregnancy, sex, birth and the postpartum period in different ways and should adapt their language and approach accordingly.
* Maternity service providers should ensure that women/people with PPH, their partners and whānau have culturally safe opportunities for discussion, reflection and debriefing where necessary after the event or antenatally in the next pregnancy as set out in the *Guidelines* *for* *Consultation with Obstetric and Medical Services*.
* Maternity service providers should monitor PPH by severity and ethnicity so that they can monitor equity, identify variations in outcome and then identify and implement areas for quality improvement based on this analysis.

# Definition of PPH

**Postpartum haemorrhage or PPH (any)**: Blood loss of 500 mL or more following vaginal birth or 1,000 mL following caesarean section birth.

* **Moderate PPH**: blood loss of 1,001–2,000 mL.
* **Severe PPH**: blood loss of more than 2,000 mL.
* **Primary PPH**: a PPH that occurs in the first 24 hours after birth.
* **Secondary PPH**: a PPH that occurs 24 hours to 6 weeks after birth.

The clinical condition of the woman/person experiencing the PPH is an important indicator of the effect of blood loss. Visual estimation of blood loss, while useful, is largely inaccurate and requires frequent refresher education.Accuracy is increased when the visual estimate is followed by weighing items that have collected the blood (linens, gauzes, drapes and pads).

Health practitioners should consider clinical symptoms and signs when monitoring blood loss:

* feeling unwell, anxious, light-headed or dizzy
* concerning changes in vital signs (eg, increased respiratory rate, tachycardia, narrowed pulse pressure, or hypotension)
* weakness or fainting; restlessness
* pallor, and/or
* oliguria or anuria.

Postpartum women/people can compensate for significant PPH with minimal physiological signs. Health practitioners should continue to assess and monitor the condition of the woman/person where small blood loss is ongoing so that PPH is recognised in a timely manner.

# Summary of guidance

PPH is a significant cause of perinatal morbidity and mortality. Early recognition and action is essential for effective treatment.

This guidance should be read together with the PPH management poster.

## Treating PPH

Early, open and ongoing communication is critical to treating PPH effectively. Communication channels include those between health practitioners as well as with the woman/person and their partner and whānau.

During PPH treatment, allocate a responsible person to the role of caring for the baby, partner and whānau. Consider whether interpretation services are required.

Take action as soon as abnormal ongoing blood loss is suspected – and before blood loss of 500 mL for vaginal birth or 1,000 mL following caesarean section birth. In any case of PPH:

* Call for help
* Measure, assess and arrest the bleeding
* Minimise the impact of blood loss and resuscitation
* Document the clinical events and interventions.

In all cases of PPH, consider the condition of the woman/person in relation to known blood loss, and if their condition worsens with no visible blood loss, assess the cause as early as possible.

In any assessment, effective treatment requires identification of cause. More than one cause may be contributing to the overall blood loss. Health practitioners should consider the 4 Ts:

1. tone
2. trauma
3. tissue
4. thrombin.

Tranexamic acid increases overall survival from primary PPH and decreases the likelihood of hysterectomy. Early administration of tranexamic acid is advised because effectiveness decreases over time following the PPH event. No benefit is gained if administration is delayed beyond three hours after the onset of the PPH event.

Saturation of oxytocin receptors in a dose-dependent manner may occur in those who have had augmented or induced labour. Those who have had augmented or induced labour may be at higher risk of PPH and usual protocols for treatment of PPH may not be as effective. Quickly advancing to other uterotonics may be appropriate.

In cases of significant blood loss, transfuse early with red blood cells to maintain tissue oxygenation. Consider transfusion support guided by conventional laboratory and point-of-care tests of coagulation and haemoglobin, where available. In urgent situations where cross-matched blood is unavailable, transfuse with O negative blood. Once blood loss stops and condition is stable, consider oral or intravenous iron replacement (0.5 mg iron per 1 mL blood loss).

Measure and document cumulative blood loss as well as the treatment provided.

It is critical that careful monitor and documentation occurs during the immediate treatment of PPH and over the next 24–48 hours. Following a PPH, complete observation of vital signs, uterine tone and blood loss frequently and record results using the Maternal Early Warning Score (MEWS) chart.

Regardless of setting, health practitioners and other employees within facilities providing labour, birthing and postnatal care should understand how to organise transfer if PPH occurs. Clear transfer protocols should be in place, along with treatment plans, to enable timely intervention and access to additional and specialist assistance when required.

## Education

Multidisciplinary emergency education that includes PPH scenarios improves care in PPH events and makes participants more confident about responding when emergencies occur.

Incorporate cultural safety into the continuing education of health practitioners. This should include an awareness of Māori health across four domains (hinengaro – mental, tinana – physical, wairua – spiritual and whānau – family), and how these apply to pregnancy, birth and postpartum tikanga, kaupapa and kawa. Health practitioners should be able to reflect on their own cultural assumptions and how these might influence their capacity to provide manaakitanga (support).

Health practitioners should encourage women/people to share their preferred pronouns.

## Communications

A PPH experience can be traumatic for the woman/person, their partner and whānau, and health practitioners. During the event, have a health practitioner available to support partners and whānau by explaining what is happening and answering any questions.

After the event, provide all those involved with the opportunity for discussion, reflection and debriefing. During the next pregnancy of the woman/person, provide them with the opportunity to discuss the previous PPH. Previous PPH is a risk factor for subsequent PPH.

Undertake an institutional case review for severe events.

# Medicines used to treat PPH

Knowing the basic pharmacological effects of medicines used to treat PPH can be useful to ensure their safe and effective use. The table below outlines the onset and duration of action, common adverse effects and precautions to take when using the medicines to treat PPH. When administering these medicines, it is important to allow sufficient time to support the expected pharmacologic response before additional management.

| **Medicine** | **Dose** | **Onset and duration** | **Adverse effects and precautions of medicine when used to treat PPH\*** |
| --- | --- | --- | --- |
| Oxytocin | After delivery of the placenta:  IV: 5 units  IM: 10 units | IV: acts within 1 minute, effect lasts 15–30 minutes  IM: acts within 2–4 minutes, effects last 30–60 minutes | Nausea and vomiting  Caution if used during labour as saturation of oxytocin receptors can occur |
| Syntometrine® (oxytocin 5 units/mL + ergometrine 500 micrograms/mL) | After delivery of the placenta:  IM: 1 mL  Can repeat 1 mL dose at intervals of no less than 2 hours, up to 3 mL in 24 hours | IM: acts within 2–3 minutes, effects last 2–4 hours | Nausea, vomiting, headaches and hypertension; increased risk of retained placenta  Do not use if:   * used in active management of the third stage of labour * the woman/person has hypertension, heart disease, pre-eclampsia, eclampsia * the woman/person has a retained placenta * medicine is cloudy or has changed colour. |
| Tranexamic acid | 1 g undiluted IV over 10 minutes (eg, 1 g/10 mL IV at 1 mL per minute)  Repeat if ongoing bleeding after 30 minutes; do not use beyond 3 hours after the onset of the PPH event | IV: acts within 5–15 minutes, effects last 3 hours | Nausea, vomiting and diarrhoea are common  Do not use if the woman/person has:   * a known thromboembolic event during pregnancy * a history of coagulopathy * active intravascular clotting * a known hypersensitivity to tranexamic acid. |
| Carboprost | IM: 250 micrograms/mL  IV: Do not administer | Peak serum concentration between 15–60 minutes, effects last 24 hours  Can be given every 15 minutes up to 8 doses | Nausea, vomiting, diarrhoea and increased temperature are very common  Do not use if the woman/person has:   * acute pelvic inflammatory disease * active cardiac, pulmonary, renal or hepatic disease * asthma. |
| Misoprostol | Sublingual: 800 micrograms  Rectal:1,000 micrograms | Peak serum concentration between 18–34 minutes, acts within 3–5 minutes, effect lasts 75 minutes | Shivering and transient elevated temperature are common  No known contraindications for postpartum use |
| Ergometrine  *Note: Ergometrine is a section 29 medicine* | After delivery of the placenta and possibility of twin pregnancy excluded:  IM: 200 micrograms | IM: acts within 2–5 minutes  IM: effects last 3 hours or longer | Severe adverse effects: IV administration should be limited to patients with severe PPH due to the risks of hypertension  Do not use if the woman/person has:   * cardiac disease * hypertension * pre-eclampsia * eclampsia * impaired renal or hepatic function * sepsis.   It has significant interactions with other medicines including antibiotics and general anaesthetics |

Note: \* See the New Zealand Formulary for a comprehensive list of contraindications, adverse effects and cautions (www.nzf.org.nz). Health practitioners should evaluate each woman/person for sensitivity related to and appropriateness of any medicine before using it.

IM = intramuscular; IV = intravenous.

# Implementation and monitoring

Maternity services are responsible for funding and operationalising the agreed recommendations within this consensus guideline. In implementing this guideline, they must consider their commitments to deliver equitable services and meet obligations under Te Tiriti. It is expected that maternity service providers will undertake data collection and monitoring of PPH locally. They should submit minimum data (as described by the Ministry of Health) to the National Minimum Dataset.

# Further advice on Te Tiriti

Health practitioners may find their professional association offers helpful support with giving effect to the principles of Te Tiriti. Such support may include:

* Medical Council of New Zealand: [Statement on cultural safety](https://www.mcnz.org.nz/assets/standards/b71d139dca/Statement-on-cultural-safety.pdf)
* Medical Council of New Zealand: [He ara hauora Māori: A pathway to Māori health equity](https://www.mcnz.org.nz/assets/standards/6c2ece58e8/He-Ara-Hauora-Maori-A-Pathway-to-Maori-Health-Equity.pdf)
* Midwifery Council of New Zealand: [Statement on cultural competence for midwives](https://www.midwiferycouncil.health.nz/common/Uploaded%20files/Registration/Statement%20on%20Cultural%20Competence.pdf)
* Turanga Kaupapa, principles that give life and meaning to the midwifery profession’s recognition of Māori as tangata whenua and the profession’s obligations under Te Tiriti, in the *Midwives’ Handbook for Practice*
* The Royal Australasian College of Physicians: [Guideline commentary on consulting with Māori and their whānau](https://www.racp.edu.au/docs/default-source/policy-and-adv/guideline-commentary-on-care-and-support-of-maori-and-their-whanau-around-the-time-of-death.pdf?sfvrsn=8a312c1a_5).

Health practitioners may also find it valuable to familiarise themselves with:

* Māuri Ora Associates: [Best health outcomes for Māori: Practice implications](http://www.indigenouspsych.org/Resources/Best_Health_Outcomes_for_Maori.pdf)
* Pitama S et al: [Improving Māori health through clinical assessment: Waikare o te Waka o Meihana](https://assets-global.website-files.com/5e332a62c703f653182faf47/5f0529a9a1ec56bf525964c9_content.pdf)
* University of Otago MIHI 501 Health Professionals Course: [Application of Hui Process and Meihana Model to Clinical Practice](https://www.otago.ac.nz/continuingeducation/about/otago731553.html).

## Cultural safety

Practising in a culturally safe way is important and a requirement of Te Tiriti, particularly in giving effect to the principles of *Active protection*, *Options* and *Partnership*. It is important that health practitioners know that tikanga or correct protocols and practices are often specific to whānau, hapū and iwi and that observing tikanga does not involve a ‘one size fits all’ approach. Similarly, mātauranga Māori or Māori knowledge is not a single entity; rather there is both traditional and contemporary mātauranga Māori, as well as mātauranga Māori that is specific to hapū and iwi environment, including land, seas, waterways, weather systems, the stars, flora and fauna, and things seen and unseen. Older forms of mātauranga Māori have been somewhat protected from colonisation because they were composed or narrated in te reo Māori.

Rangatiratanga or self-determining rights over tikanga and mātauranga Māori is crucial to its safety and survival. For this reason, health practitioners should be very careful to avoid imposing their understanding of tikanga or mātauranga Māori on Māori through maternity care. In addition, they should not assume that all Māori are familiar with terms such as tikanga, mātauranga and Te Tiriti. Māori who are unfamiliar with such terms can experience such an assumption as diminishing their mana[[6]](#footnote-6) as expressed by Te Tiriti, which would be an outcome that is the opposite of the intent of Te Tiriti, this consensus guideline and *Ngā paerewa*.

# Development process

The Ministry of Health contracted Allen + Clarketo update the 2013 *National Consensus Guideline for Treatment of Postpartum Haemorrhage*. Our project team (Anna Gribble, Professor Frank Bloomfield, Dr Michelle Wise and Norma Campbell) is grateful for the advice and guidance received from the sector in response to draft documents. Two literature reviews addressing five research questions were completed to inform the update of this consensus guideline. Recommendations were developed by expert consensus, considering the evidence from the reviews of relevant clinical literature.

We wish to acknowledge and thank the Maternity Guidelines Review Steering Group for its advice and guidance. Members of the Maternity Guidelines Review Steering Group were:

* Dr Angela Beard (Co-Chair, He Hono Wahine)
* Sue Bree (Co-Chair, Midwifery Leaders’ Group)
* Claire MacDonald (NZ College of Midwives)
* Dr Karaponi Okesene Gafa (Royal Australian and New Zealand College of Obstetricians and Gynaecologists, RANZCOG)
* Dr Lesley Dixon (NZ College of Midwives)
* Liz Lewis-Hills (New Zealand Society for the Study of Diabetes)
* Dr Mariam Buksh (Royal Australasian College of Physicians)
* Dr Matthew Drake (Australian and New Zealand College of Anaesthetists)
* Dr Rachael McConnell (RANZCOG)
* Dr Rosemary Hall (New Zealand Society for the Study of Diabetes)
* Dr Sue Belgrave (RANZCOG)
* Dr Trevor Lloyd (Royal New Zealand College of General Practitioners).

# Bibliography

## Measuring, assessing and arresting blood loss

### Estimating blood loss

#### New references

Diaz V, Abalos E, Carroli G. Methods for blood loss estimation after vaginal birth. *Cochrane Database Syst Rev* 2018, Issue 9, Art. No. CD010980. DOI: 10.1002/14651858.CD010980.pub2 (accessed 2 February 2022).

Goodman A. 2015. Pictorial estimation of blood loss in a birthing pool: an aide memoire. *Practising Midwife* 18(4): 29–32.

Hancock A, Weeks AD, Lavender DT. 2015. Is accurate and reliable blood loss estimation the ‘crucial step’ in early detection of postpartum haemorrhage: an integrative review of the literature. *BMC Pregnancy Childbirth* 15: 230.

Pacagnella RC, Souza JP, Durocher J, et al. 2013. A systematic review of the relationship between blood loss and clinical signs. *PLOS ONE* 8(3): e57594.

Quantification of blood loss: AWHONN practice brief number 1. 2015. *Journal of Obstetric, Gynecologic, and Neonatal Nursing* 44(1): 158–60.

Toledo P, Eosakul ST, Goetz K, et al. 2012. Decay in blood loss estimation skills after web-based didactic training. *Simulation in Healthcare* 7(1): 18–21.

Withanathantrige M, Goonewardene M, Dandeniya R, et al. 2016. Comparison of four methods of blood loss estimation after cesarean delivery. *International Journal of Gynaecology and Obstetrics* 135(1): 51–5.

Zuckerwise LC, Pettker CM, Illuzzi J, et al. 2014. Use of a novel visual aid to improve estimation of obstetric blood loss. *Obstetrics and Gynecology* 123(5): 982–6.

#### Original references

Baldwin S, Rucklidge M. 2009. Management of obstetric haemorrhage*. Update in Anaesthesia* 25(2): 41–8. URL: <http://update.anaesthesiologists.org/wp-content/uploads/2010/07/Update-252.pdf> (accessed on 6 May 2013).

Bose P, Regan F, Paterson-Brown S. 2006. Improving the accuracy of estimated blood loss at obstetric haemorrhage using clinical reconstructions*. BJOG: An International Journal of Obstetrics and Gynaecology* 113(8): 919–24.

Dildy GA, Paine AR, George NC, et al. 2004. Estimating blood loss: can teaching significantly improve visual estimation? *Obstetrics and Gynecology* 104(3): 601–6.

Patel A, Goudar SS, Geller SE, et al. 2006. Drape estimation vs. visual assessment for estimating postpartum hemorrhage. *International Journal of Gynecology and Obstetrics* 93(3): 220–4.

Sloan NL, Durocher J, Aldrich T, et al. 2010. What measured blood loss tells us about postpartum bleeding: a systematic review. *BJOG: An International Journal of Obstetrics and Gynaecology* 117(2): 788–800.

Toledo P, McCarthy RJ, Hewlett BJ, et al. 2008.The accuracy of blood loss estimation after simulated vaginal delivery. *Obstetric Anesthesia Digest* 28(3): 172–3.

Zhang WH, Deneux-Tharaux C, Brocklehurst P, et al, on behalf of Euphrates Group. 2010.Effect of a collector bag for measurement of postpartum blood loss after vaginal delivery: cluster randomised trial in 13 European countries*. BMJ* 340: 293.

Zwart JJ, Yazdani ST, Harvey MS, et al. 2010.Under reporting of major obstetric haemorrhage in the Netherlands. *Transfusion Medicine* 20(2): 118–22.

### Uterotonics

#### New references

Balki M, Erik-Soussi M, Kingdom J, et al. 2014. Comparative efficacy of uterotonic agents: in vitro contractions in isolated myometrial strips of labouring and non-labouring women. *Canadian Journal of Anesthesia/Journal canadien d’anesthésie* 61(9): 808–18.

Balki M, Ramachandran N, Lee S, et al. 2016. The recovery time of myometrial responsiveness after oxytocin-induced desensitization in human myometrium in vitro. *Anesthesia & Analgesia* 122(5): 1508–15.

Butwick AJ, Carvalho B, Blumenfeld YJ, et al. 2015. Second-line uterotonics and the risk of hemorrhage-related morbidity. *American Journal of Obstetrics and Gynecology* 212(5): 642: e641–647.

Cole NM, Carvalho JCA, Erik-Soussi M, et al. 2016. In vitro comparative effect of carbetocin and oxytocin in pregnant human myometrium with and without oxytocin pretreatment. *Anesthesiology* 124(2): 378–86. DOI: 10.1097/ALN.[0000000000000940](https://doi.org/10.1097/aln.0000000000000940) (accessed 3 February 2022).

Dagdeviren H, Cengiz H, Heydarova U, et al. 2016. Intramuscular versus intravenous prophylactic oxytocin for postpartum hemorrhage after vaginal delivery: a randomized controlled study*. Archives of Gynecology and Obstetrics* 294(5): 911–6.

Gallos ID, Williams HM, Price MJ, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta‐analysis. *Cochrane Database Syst Rev* 2015, Issue 5, Art. No. CD011689. DOI: 10.1002/14651858.CD011689 (accessed 3 February 2022).

Mousa HA, Blum J, Abou El Senoun G, et al. Treatment for primary postpartum haemorrhage. *Cochrane Database Syst Rev* 2014, Issue 2, Art. No. CD003249. DOI: [10.1002/14651858.CD003249.pub3](https://doi.org/10.1002/14651858.cd003249.pub3) (accessed 3 February 2022).

Muir HA. 2013. Pharmacologic intervention for managing uterine atony and related maternal hemorrhage: what is the most effective drug dose? *Canadian Journal of Anaesthesia/Journal canadien d’anesthésie* 60(11): 1047–53.

Robinson C, Schumann R, Zhang PS, et al. 2003. Oxytocin-induced desensitization of the oxytocin receptor. *American Journal of Obstetrics and Gynecology* 188(2): 497–502.

#### Original references

Belghiti J, Kayem G, Dupont C, et al. 2011. Oxytocin during labour and risk of severe postpartum haemorrhage: a population based, cohort-nested case – control study*. BMJ Open* 1(2): e000514. DOI: 10.1136/bmjopen-2011-000514 (accessed 4 February 2022).

Buekens P, Althabe P. 2010. Post-partum haemorrhage: beyond the confrontation between misoprostol and oxytocin. *The Lancet* 375(9710): 176–8.

Choy CMY, Lau WC, Tam WH, et al.2002. A randomised controlled trial of intramuscular syntometrine and intravenous oxytocin in the management of the third stage of labour*.* *BJOG: An International Journal of Obstetrics and Gynaecology* 109: 173–7.

Liabsuetrakul T, Choobun T, Peeyananjarassri K, et al. Prophylactic use of ergot alkaloids in the third stage of labour*. Cochrane Database Syst Rev* 2007,Issue 2, Art. No. CD005456. DOI: 10.1002/14651858.CD005456.pub2 (accessed 6 May 2013).

WHO. 2012. *WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage.* Geneva: World Health Organization. URL: <http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241548502/en/> (accessed 6 May 2013).

### Carboprost

#### Original reference

Tuncalp O, Hofmeyr GJ, Gulmezoglu AM. Prostaglandins for prevention of postpartum haemorrhage. *Cochrane Database Syst Rev* 2012, Issue 8, Art. No. CD000494. DOI: 10.1002/14651858.CD000494.pub4 (accessed 4 February 2022).

### Misoprostol

#### New references

Dabash R, Blum J, Raghavan S, et al. 2012. Misoprostol for the management of postpartum bleeding: a new approach. *International Journal of Gynaecology and Obstetrics* 119(3): 210–2.

Gibbins KJ, Albright CM, Rouse DJ. 2013. Postpartum hemorrhage in the developed world: whither misoprostol? *American Journal of Obstetrics and Gynecology* 208(3): 181–3.

International Federation of Gynecology and Obstetrics. 2012. Treatment of postpartum hemorrhage with misoprostol. *International Journal of Gynaecology and Obstetrics* 119(3): 215–6.

Olefile KM, Khondowe O, M’Rithaa D. 2013. Misoprostol for prevention and treatment of postpartum haemorrhage: a systematic review. *Curationis* 36(1): E1–10.

Prata N, Weidert K. 2016. Efficacy of misoprostol for the treatment of postpartum hemorrhage: current knowledge and implications for health care planning. *International Journal of Women’s Health* 8: 341–9.

#### Original references

Blum J, Winikoff B, Raghavan S, et al. 2010. Treatment of postpartum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial. *The Lancet* 375(9710): 217–23.

Gülmezoglu M, Villar J, Ngoc N, et al. 2001. WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. *The Lancet* 358(9283): 689–95.

Hofmeyer GJ, Walraven G, Gulmezoglu AM, et al. 2005. Misoprostol to treat postpartum haemorrhage: a systematic review. *BJOG: An International Journal of Obstetrics and Gynaecology* 112(5): 547–53.

Khan RU, El-Refaey H, Sharma S, et al. 2004. Oral, rectal and vaginal pharmacokinetics of misoprostol. *Obstetrics and Gynecology* 103(5, Pt 1): 866–70.

O’Brien P, El-Refaey H, Gordon A, et al. 1998. Rectally administered misoprostol for the treatment of postpartum haemorrhage unresponsive to syntocinon and ergometrine: a descriptive study. *Obstetrics and Gynecology* 92(2): 212–4.

Widmer M, Blum J, Hofmeyer GJ, et al. 2010. Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage: a multicentre, double-blind randomised trial. *The Lancet* 375(9728): 1808–13.

Winikoff B, Dabash R, Duracher J, et al. 2010. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial. *The Lancet* 375(9710): 210–6.

### Tranexamic acid

#### New references

Bouet P-E, Ruiz V, Legendre G, et al. 2016. Policy of high-dose tranexamic acid for treating postpartum hemorrhage after vaginal delivery. *Journal of Maternal-Fetal & Neonatal Medicine* 29(10): 1617–22.

Della Corte L, Saccone G, Locci M, et al. 2020. Tranexamic acid for treatment of primary postpartum hemorrhage after vaginal delivery: a systematic review and meta-analysis of randomized controlled trials. *Journal of Maternal-Fetal & Neonatal Medicine* 33(5): 869–74.

Diop A, Abbas D, Ngoc NTN, et al. 2020. A double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for the treatment for postpartum hemorrhage. *Reproductive Health* 17(1): 34.

Ducloy-Bouthors AS, Duhamel A, Kipnis E, et al. 2016. Postpartum haemorrhage related early increase in D-dimers is inhibited by tranexamic acid: haemostasis parameters of a randomized controlled open labelled trial. *British Journal of Anaesthesia* 116(5): 641–8.

Faraoni D, Carlier C, Samama CM, et al. 2014. Efficacy and safety of tranexamic acid administration for the prevention and/or the treatment of post-partum haemorrhage: a systematic review with meta-analysis. *Annales françaises d’anesthésie et de réanimation* 33(11): 563–71.

Gayet-Ageron A, Prieto-Merino D, Ker K, et al. 2018. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40,138 bleeding patients. *The Lancet* 391(10116): 125–32.

Gillissen A, Henriquez DD, van den Akker T, et al. 2017. The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: a nationwide retrospective cohort study. *PLOS ONE* 12(11): e0187555.

Maternal and Child Survival Program, World Health Organisation. 2017. Updated WHO recommendation on tranexamic acid for the treatment of postpartum haemorrhage. URL: <http://www.mcsprogram.org/resource-search-results/?_sf_s=tranexamic> (accessed 4 February 2022).

Picetti R, Shakur-Still H, Medcalf RL, et al. 2019. What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. *Blood Coagulation & Fibrinolysis* 30(1): 1–10.

Shakur H, Beaumont D, Pavord S, et al. Antifibrinolytic drugs for treating primary postpartum haemorrhage. *Cochrane Database Syst Rev* 2018, Issue 2, Art. No. CD012964. DOI: 10.1002/14651858.CD012964 (accessed 4 February 2022).

Shakur-Still H, Roberts I, Fawole B, et al. 2018. Effect of tranexamic acid on coagulation and fibrinolysis in women with postpartum haemorrhage (WOMAN-ETAC): a single-centre, randomised, double-blind, placebo-controlled trial. *Wellcome Open Research* 3: 100.

WOMAN Trial Collaborators. 2017. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. *The Lancet* 389(10084): 2105–16.

#### Original references

Alok AK, Hagen P, Webb JB. 1996. Tranexamic acid in the management of postpartum haemorrhage. *BJOG: An International Journal of Obstetrics and Gynaecology* 103(12): 1250–1.

Peitsidis P, Kadir RA. 2011. Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. *Expert Opinion Pharmacotherapy* 12(4): 503–16.

### Carbetocin

#### New references

Maged AM, Hassan AMA, Shehata NAA. 2016. Carbetocin versus oxytocin in the management of atonic post partum haemorrhage (PPH) after vaginal delivery: a randomised controlled trial. *Archives of Gynecology and Obstetrics* 293(5): 993–9.

Razali N, Md Latar IL, Chan YK, et al. 2016. Carbetocin compared to oxytocin in emergency cesarean section: a randomized trial. *European Journal of Obstetrics & Gynecology and Reproductive Biology* 198: 35–9.

#### Original references

Askar AA, Ismail MT, Amro AE, et al. 2011. Carbetocin v syntometrine in the management of third stage of labour following vaginal delivery. *Archives of Gynecology and Obstetrics* 284(6): 1359–65.

Dansereau J, Joshi A, Helewa M, et al. 1999. Double blinded comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. *American Journal of Obstetrics and Gynecology* 180(3, Pt 1): 670–6.

Leung SW, Ng PS, Wong WY, et al. 2006. A randomised control of carbetocin versus syntometrine in the management of third stage of labour. *BJOG: An International Journal of Obstetrics and Gynaecology* 113(12): 1459–64.

Su LL, Rauff M, Chan YH, et al. 2009. Carbetocin versus syntometrine for the third stage of labour following vaginal delivery: a double-blind randomised controlled trial. *BJOG: An International Journal of Obstetrics and Gynaecology* 116(11): 1461–6.

### Coagulation

#### New references

Butwick AJ, Goodnough LT. 2015. Transfusion and coagulation management in major obstetric hemorrhage. *Current Opinion in Anaesthesiology* 28(3): 275–84.

Collins PW, Bell SF, de Lloyd L, et al. 2019. Management of postpartum haemorrhage: from research into practice, a narrative review of the literature and the Cardiff experience. *International Journal of Obstetric Anesthesia* 37: 106–17.

Collins PW, Lilley G, Bruynseels D, et al. 2014. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. *Blood* 124(11): 1727–36.

Collins P, Abdul-Kadir R, Thachil J. 2016. Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis* 14(1): 205–10.

Cortet M, Deneux-Tharaux C, Dupont C, et al. (2012). Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. *British Journal of Anaesthesia* 108(6): 984–9.

de Lange NM, Lancé MD, de Groot R, et al. 2012. Obstetric hemorrhage and coagulation: an update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage. *Obstetrical & Gynecological Survey* 67(7): 426–35.

Ekelund K, Hanke G, Stensballe J, et al. 2015. Hemostatic resuscitation in postpartum hemorrhage: a supplement to surgery. *Acta Obstetricia et Gynecologica Scandinavica* 94(7): 680–92.

Gillissen A, van den Akker T, Caram-Deelder C, et al. 2018. Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study. *Blood Advances* 2(19): 2433–42.

Hill JS, Devenie G, Powell M. 2012. Point-of-care testing of coagulation and fibrinolytic status during postpartum haemorrhage: developing a thrombelastography®-guided transfusion algorithm. *Anaesthesia and Intensive Care* 40(6): 1007–15.

James AH, Grotegut C, Ahmadzia H, et al. 2016. Management of coagulopathy in postpartum hemorrhage. *Seminars in Thrombosis and Hemostasis* 42(7): 724–31.

Karlsson O, Jeppsson A, Hellgren M. 2014. Major obstetric haemorrhage: monitoring with thromboelastography, laboratory analyses or both? *International Journal of Obstetric Anesthesia* 23(1): 10–7.

Mallaiah S, Barclay P, Harrod I, et al. 2015. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. *Anaesthesia* 70(2): 166–75.

Mallett SV, Armstrong M. 2015. Point-of-care monitoring of haemostasis. *Anaesthesia* 70(Suppl 1): 73–7.

McNamara H, Kenyon C, Smith R, et al. 2019. Four years’ experience of a ROTEM®-guided algorithm for treatment of coagulopathy in obstetric haemorrhage. *Anaesthesia* 74(8): 984–91.

Oh KJ, Hong J-S, Youm J, et al. 2016. Can coagulopathy in post-partum hemorrhage predict maternal morbidity? *Journal of Obstetrics and Gynaecology Research* 42(11): 1509–18.

Shreeve NE, Barry JA, Deutsch LR, et al. 2016. Changes in thromboelastography parameters in pregnancy, labor, and the immediate postpartum period. *International Journal of Gynaecology and Obstetrics* 134(3): 290–3.

Sohn CH, Kim Y-J, Seo DW, et al. 2018. Blood lactate concentration and shock index associated with massive transfusion in emergency department patients with primary postpartum haemorrhage. *British Journal of Anaesthesia* 121(2): 378–83.

Wikkelsø AJ, Edwards HM, Afshari A, et al. 2015. Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. *British Journal of Anaesthesia* 114(4): 623–33.

Yamada T, Akaishi R, Oda Y, et al. 2014. Antenatal fibrinogen concentrations and postpartum haemorrhage. *International Journal of Obstetric Anesthesia* 23(4): 365–70.

#### Original reference

Poe MF. 1959. Clot observation test for clinical diagnosis of clotting defects*. Anesthesiology* 20: 825–9.

### Uterine compression balloons

#### New references

Einerson BD, Son M, Schneider P, et al. 2017. The association between intrauterine balloon tamponade duration and postpartum hemorrhage outcomes. *American Journal of Obstetrics and Gynecology* 216(3): 300.e1–5.

Gauchotte E, De La Torre M, Perdriolle-Galet E, et al. 2017. Impact of uterine balloon tamponade on the use of invasive procedures in severe postpartum hemorrhage. *Acta Obstetricia et Gynecologica Scandinavica* 96(7): 877–82.

Lo A, St Marie P, Yadav P, et al. 2016. The impact of Bakri balloon tamponade on the rate of postpartum hysterectomy for uterine atony. *Journal of Maternal-Fetal & Neonatal Medicine* 1–4.

Revert M, Cottenet J, Raynal P, et al. 2016. Intrauterine balloon tamponade for management of severe postpartum haemorrhage in a perinatal network: a prospective cohort study. *British Journal of Obstetrics and Gynaecology* 124(8): 1255–62.

Wright CE, Chauhan SP, Abuhamad AZ. 2014. Bakri balloon in the management of postpartum hemorrhage: a review. *American Journal of Perinatology* 31(11): 957–63.

Yan JY, Zhou Z-M, Xu X, et al. 2014. Risk factors and surgical interventions associated with primary postpartum haemorrhage unresponsive to first-line therapies. *Journal of Obstetrics and Gynaecology* 34(7): 588–92.

Yoong W, Ridout A, Memtsa M, et al. 2012. Application of uterine compression suture in association with intrauterine balloon tamponade (‘uterine sandwich’) for postpartum hemorrhage. *Acta Obstetricia et Gynecologica Scandinavica* 91(1): 147–51.

#### Original references

Bakri YN, Amri A, Abdul Jabber F. 2001.Tamponade-balloon for obstetrical bleeding. *International Journal of Gynaecology and Obstetrics* 74(2): 139–42.

Condous GS, Arulkumaran S, Symonds I, et al. 2003.The ‘tamponade test’ in the management of massive postpartum haemorrhage. *Obstetrics and Gynecology* 101(4): 767–72.

Danso D, Reginald P. 2002.Combined B-Lynch suture with intrauterine balloon catheter triumphs over massive postpartum haemorrhage. *BJOG: An International Journal of Obstetrics and Gynaecology* 109(8): 963.

Georgiou C. 2009. Balloon tamponade in the management of postpartum haemorrhage: a review. *BJOG: An International Journal of Obstetrics and Gynaecology* 116(6): 748–57.

Johanson R, Kumar M, Obhrai M, et al. 2001. Management of massive postpartum haemorrhage: use of a hydrostatic balloon catheter to avoid laparotomy. *BJOG: An International Journal of Obstetrics and Gynaecology* 108(4): 420–2.

Sinha SM. 2003. The ‘tamponade test’ in the management of massive postpartum haemorrhage. *Obstetrics and Gynecology* 102(3): 641–2.

### Uterine packing gauze

#### New references

Ge J, Liao H, Duan L, et al. 2012. Uterine packing during cesarean section in the management of intractable hemorrhage in central placenta previa. *Archives of Gynecology and Obstetrics* 285(2): 285–9.

Guo YN, Ma J, Wang XJ, et al. 2015. Does uterine gauze packing increase the risk of puerperal morbidity in the management of postpartum hemorrhage during caesarean section: a retrospective cohort study. *International Journal of Clinical and Experimental Medicine* 8(8): 13740–7.

Schmid BC, Rezniczek GA, Rolf N, et al. 2013. Uterine packing with chitosan-covered gauze for control of postpartum hemorrhage. *American Journal of Obstetrics and Gynecology* 209(3): 225.e1–5.

#### Original references

Bagga R, Jain V, Kalra J, et al. 2004. Uterovaginal packing with rolled gauze in postpartum hemorrhage. *Medscape General Medicine* 6(1): 50.

Hsu S, Rodgers B, Lele A, et al. 2003. Use of packing in obstetric hemorrhage of uterine origin. *Journal of Reproductive Medicine* 48(2): 69–71.

Maier RC. 1993. Control of postpartum hemorrhage with uterine packing. *American Journal of Obstetrics and Gynecology* 169(2, Pt1): 317–21.

### Stepwise devascularisation of the uterus / B-Lynch / brace sutures

#### New references

Akbayir O, Corbacioglu Esmer A, Cilesiz Goksedef P, et al. 2013. Single square hemostatic suture for postpartum hemorrhage secondary to uterine atony. *Archives of Gynecology and Obstetrics* 287(1): 25–9.

Cowan AD, Miller ES, Grobman WA. 2014. Subsequent pregnancy outcome after B‑lynch suture placement. *Obstetrics and Gynecology* 124(3): 558–61.

El-Sokkary M, Wahba K, El-Shahawy Y. 2016. Uterine salvage management for atonic postpartum hemorrhage using ‘modified lynch suture’. *BMC Pregnancy and Childbirth* 16: 251.

Maher MA, Abdelaziz A. 2017. Comparison between two management protocols for postpartum hemorrhage during cesarean section in placenta previa: balloon protocol versus non-balloon protocol. *Journal of Obstetrics & Gynaecology Research*  
43(3): 447–55.

Sathe NA, Likis FE, Young JL, et al. 2016. Procedures and uterine-sparing surgeries for managing postpartum hemorrhage: a systematic review. *Obstetrical & Gynecological Survey* 71(2): 99–113.

#### Original references

AbdRabbo SA. 1994*.* Stepwise uterine devascularization: a novel technique for management of uncontrolled postpartum hemorrhage with preservation of the uterus. *American Journal of Obstetrics and Gynecology* 171(3): 694–700.

Allam NS, B-Lynch C. 2005. The B-Lynch and other uterine compression suture techniques. *International Journal of Gynaecology and Obstetrics* 89(3): 236–41.

B-Lynch C, Coker A, Lawal AH, et al. 1997. The B-Lynch technique for the control of massive obstetric haemorrhage: an alternative to hysterectomy? Five cases reported. *BJOG: An International Journal of Obstetrics and Gynaecology* 104(3): 372–5.

Kayem G, Kurinczuk J, Alfirevic Z, et al. 2011. Specific second-line therapies for postpartum haemorrhage: a national cohort study. *BJOG: An International Journal of Obstetrics and Gynaecology* 118(7): 856–64.

Lombaard H, Pattinson RC. 2009. Common errors and remedies in managing postpartum haemorrhage. *Best Practice and Research Clinical Obstetrics and Gynaecology* 23(3): 317–26.

Mallappa Saroja CS, Nankani A, El-Hamamy E*.* 2010. Uterine compression sutures, an update: review of efficacy safety and complications of B-Lynch sutures and other uterine compression techniques for postpartum haemorrhage. *Archives of Gynaecology and Obstetrics* 281(4): 581–8.

Ouahba J, Piketty M, Huel C, et al. 2007. Uterine compression sutures for postpartum bleeding with uterine atony. *BJOG: An International Journal of Obstetrics and Gynaecology* 114(5): 619–22.

Sentilhes L, Gromez A, Razzouk K, et al. 2008. B-Lynch suture for massive persistent postpartum hemorrhage following stepwise uterine devascularization. *Acta Obstetricia et Gynecologica* 87(10): 1020–6.

Sentilhes L, Gomez A, Trichot C, et al. 2009. Fertility after B-Lynch suture and stepwise uterine devascularization. *Fertility and Sterility* 91(3): 934.e5–9.

Tsvetkov K, Angelova M, Monastirska M, et al. 2008. About stepwise uterine devascularisation in early post-partum haemorrhages. *Akusherstvo i Ginekologiia* 47(5): 34–7.

Wergeland H, Alagic E, Lokvik B. 2002. Use of the B-Lynch suture technique in postpartum hemorrhage. *Tidsskr* *Nor Laegeforen* 122(4): 370–2.

### Fibrin glues and gel

#### New reference

Pellerin O, Bats A-S, Di Primio M, et al. 2013. Postpartum hemorrhage treated with gelfoam slurry embolization using the superselective technique: immediate results and 1-month MRI follow-up. *Cardiovascular and Interventional Radiology* 36(1): 98–104.

#### Original references

Nelson WL, O’Brien JM. 2007. Uterine sandwich for persistent uterine atony: combining the B‑Lynch compression suture and an intrauterine Bakri balloon. *American Journal of Obstetrics and Gynecology* 196(5): e9–10.

Palacios-Jaraquemada J, Fiorillo A. 2010. Conservative approach in heavy postpartum hemorrhage associated with coagulopathy. *Acta Obstetricia et Gynecologica* 89(9): 1222–5.

### Artery ligation/embolism

#### New references

Kim Y-J, Yoon CJ, Seong NJ, et al. 2013. Failed pelvic arterial embolization for postpartum hemorrhage: clinical outcomes and predictive factors*. Journal of Vascular and Interventional Radiology* 24(5): 703–9.

Lo T-K, So C-H, Yeung WS, et al. 2017. Comparison of selective and non-selective internal iliac artery embolization for abnormal placentation with major postpartum hemorrhage. *International Journal of Gynaecology and Obstetrics* 136(1): 103–4.

Niola R, Cavaliere C, Marcello L, et al. 2014. Role of interventional radiology in treating obstetric haemorrhages. *La Radiologia medica* 119(8): 607–15.

Park KJ, Shin JH, Yoon HK, et al. 2015. Postpartum hemorrhage from extravasation or pseudoaneurysm: efficacy of transcatheter arterial embolization using N-butyl cyanoacrylate and comparison with gelatin sponge particle. *Journal of Vascular and Interventional Radiology* 26(2): 154–61.

Xu JQ. 2015. Effectiveness of embolization of the internal iliac or uterine arteries in the treatment of massive obstetrical and gynecological hemorrhages. *European Review for Medical and Pharmacological Sciences* 19(3): 372–4.

Yamasaki Y, Morita H, Miyahara Y, et al. 2014. The factors associated with the failure of transcatheter pelvic arterial embolization for intractable postpartum hemorrhage. *Journal of Perinatal Medicine* 42(3): 359–62.

#### Original references

Allahbadia G. 1993. Hypogastric artery ligation: a new perspective. *Journal of Gynecologic Surgery* 9(1): 35–42.

Cheng YY, Hwang JI, Hung SW, et al. 2003. Angiographic embolization for emergent and prophylactic management of placenta accreta: a four-year experience. *Journal of the Chinese Medical Association* 66(12): 727–34.

Chou MM, Hwang JI, Tseng JJ, et al. 2003. Internal iliac artery embolization before hysterectomy for placenta accreta. *Journal of Vascular and Interventional Radiology* 14(9, Pt 1): 1195–9.

Clark SL, Phelan JP, Yeh SY, et al. 1985. Hypogastric artery ligation for obstetric hemorrhage. *Obstetrics and Gynecology* 66(3): 353–6.

Maassen MS, Lambers MD, Tutein Nolthenius RP, et al. 2009. Complications and failure of uterine artery embolisation for intractable postpartum haemorrhage*. BJOG: An International Journal of Obstetrics and Gynaecology* 116(1): 55–61.

Ojala K, Perala J, Kariniemi J, et al. 2005. Arterial embolization and prophylactic catheterization for the treatment of severe obstetric hemorrhage. *Acta Obstetricia et Gynecologica* 84(11): 1075–80.

O’Leary JA. 1995. Uterine artery ligation in the control of post-caesarean hemorrhage. *Journal of Reproductive Medicine* 40(3): 189–93.

O’Leary JL, O’Leary JA. 1974. Uterine artery ligation for control of post-cesarean section hemorrhage. *Obstetrics and Gynecology* 43(6): 849–53.

Winograd RH. 2008. Uterine artery embolization for postpartum haemorrhage. *Best Practice Research Clinical Obstetrics and Gynaecology* 22(6): 1119–32. DOI: 10.1016/j.bpobgyn.2008.08.009 (accessed 4 February 2022).

### Hysterectomy

#### Original references

Knight M. 2007. Peripartum hysterectomy in the UK: management and outcomes of the associated haemorrhage*. BJOG: An International Journal of Obstetrics and Gynaecology* 114(11): 1380–7.

Knight M, Kurinczuk JJ, Spark P, et al. 2008. Cesarean delivery and peripartum hysterectomy*. Obstetrics and Gynecology* 111(1): 97–105.

Lone F, Sultan AH, Thakar R, et al. 2010. Risk factors and management patterns for emergency obstetric hysterectomy over two decades*. International Journal of Gynaecology and Obstetrics* 109(1): 12–5*.*

Rossi AC, Lee RH, Chmait RH. 2010. Emergency postpartum hysterectomy for uncontrolled postpartum bleeding: a systematic review. *Obstetrics and Gynecology* 115(3): 637–44.

Turner MJ. 2010. Peripartum hysterectomy: an evolving picture. *International Journal of Gynaecology and Obstetrics* 109(1): 9–11.

## Minimising impact of blood loss and resuscitation

### Crystalloids and colloids

#### New references

Collis RE, Collins PW. 2015. Haemostatic management of obstetric haemorrhage. *Anaesthesia* 70(Suppl 1): 78–86.

Schorn MN, Phillippi JC. 2014. Volume replacement following severe postpartum hemorrhage. *Journal of Midwifery and Women’s Health* 59(3): 336–43.

#### Original references

Fuller AJ, Bucklin BA. 2010. Blood product replacement for postpartum hemorrhage. *Clinical Obstetrics and Gynecology* 53(1): 196–208.

Schierhout G, Roberts I. 1998. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. *BMJ* 316(7136): 961–4.

Stainsby D, MacLennan S, Thomas D, et al. 2006. Guidelines on the management of massive blood loss. *British Journal of Haematology* 135(5): 634–41.

### Blood and blood products

#### New references

Bonnet MP, Basso O. 2012. Prohemostatic interventions in obstetric hemorrhage. *Seminars in Thrombosis and Hemostasis* 38(3): 259–64.

Bonnet M-P, Deneux-Tharaux C, Dupont C, et al. 2013. Transfusion practices in postpartum hemorrhage: a population-based study. *Acta Obstetricia et Gynecologica Scandinavica* 92(4): 404–13.

Green L, Knight M, Seeney FM, et al. 2016. The epidemiology and outcomes of women with postpartum haemorrhage requiring massive transfusion with eight or more units of red cells: a national cross-sectional study. *BJOG: An International Journal of Obstetrics and Gynaecology* 123(13): 2164–70.

Guasch E, Gilsanz F. 2016. Treatment of postpartum hemorrhage with blood products in a tertiary hospital: outcomes and predictive factors associated with severe hemorrhage. *Clinical and Applied Thrombosis/Hemostasis* 22(7): 685–92.

Pasquier P, Gayat E, Rackelboom T, et al. 2013. An observational study of the fresh frozen plasma: red blood cell ratio in postpartum hemorrhage. *Anesthesia and Analgesia* 116(1): 155–61.

Waters JH. 2014. Patient blood management in obstetrics. *International Anesthesiology Clinics* 52(3): 85–100.

Wikkelsø AJ, Hjortøe S, Gerds TA, et al. 2014. Prediction of postpartum blood transfusion: risk factors and recurrence. *Journal of Maternal-Fetal & Neonatal Medicine* 27(17): 1661–7.

#### Original references

James A, McLintock C, Lockhart E. 2012. Postpartum haemorrhage: when uterotonics and sutures fail. *American Journal of Hematology* 87(S1): S16–22. DOI: [10.1002/ajh.23156/pdf](http://onlinelibrary.wiley.com/doi/10.1002/ajh.23156/pdf) (accessed 1 July 2013).

Royal College of Obstetricians and Gynaecologists. 2007. Blood transfusions in obstetrics. *Green-top Guideline No. 47*. Amended July 2008.URL: [www.rcog.org.uk/files/rcog-corp/uploaded-files/GT47BloodTransfusions1207amended.pdf](http://www.rcog.org.uk/files/rcog-corp/uploaded-files/GT47BloodTransfusions1207amended.pdf) (accessed 6 May 2013).

### Recombinant factor VII (rFVIIa)

#### New references

Ahonen J. 2012. The role of recombinant activated factor VII in obstetric hemorrhage. *Current Opinion in Anesthesiology* 25(3): 309–14.

Huber AW, Raio L, Alberio L, et al. 2012. Recombinant human factor VIIa prevents hysterectomy in severe postpartum hemorrhage: single center study. *Journal of Perinatal Medicine* 40(1): 43–9.

Lavigne-Lissalde G, Aya AG, Mercier FJ, et al. 2015. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. *Journal of Thrombosis and Haemostasis* 13(4): 520–9.

#### Original references

Ahonen J, Jokela R. 2005. Recombinant factor VIIa for life threatening post-partum haemorrhage. *British Journal of Anaesthesia* 94(5): 592–5.

Franchini M, Franchi M, Bergamini V, et al. 2010. The use of rFVII in obstetric haemorrhage. *Clinical Obstetrics and Gynecology* 53(1): 219–27.

Levi M, Levy JH, Andersen HF, et al. 2010. Safety of recombinant activated factor VII in randomized clinical trials. *New England Journal of Medicine* 363(19): 1791–800.

Pepas LP, Arif-Adib M, Kadir RA. 2006. Factor VIIa in puerperal hemorrhage with disseminated intravascular coagulation. *Obstetrics and Gynecology* 108(3, Pt 2): 757–61.

Segal S, Hemesh JY, Blumenthal B, et al. 2003. Treatment of obstetric haemorrhage with recombinant activated factor VII (rVIIa)*. Archives of Gynecology and Obstetrics* 268(4): 266–7.

Tanchev S, Platikanov V, Karadimov D. 2005. Administration of recombinant factor VIIa for the management of massive bleeding due to uterine atonia in the post-placental period*.* *Acta Obstetricia et Gynecologica* 84(4): 402–3.

### Aortic compression

#### New references

Riley DP, Burgess DW. 1994. External abdominal aortic compression: a study of a resuscitation manoeuvre for postpartum haemorrhage*. Anaesthesia and Intensive Care* 22(5): 571–5.

Stensaeth KH, Sovik E, Haig IN, et al. 2017. Fluoroscopy-free Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for controlling life threatening postpartum hemorrhage. *PLOS ONE* 12(3): e0174520.

### Intra-operative cell salvage (IOCS)

#### New references

Goucher H, Wong CA, Patel SK, et al. 2015. Cell salvage in obstetrics. *Anesthesia and Analgesia* 121(2): 465–8.

Milne ME, Yazer MH, Waters JH. 2015. Red blood cell salvage during obstetric hemorrhage. *Obstetrics and Gynecology* 125(4): 919–23.

Teare KM, Sullivan IJ, Ralph CJ. 2015. Is cell salvaged vaginal blood loss suitable for re‑infusion? *International Journal of Obstetric Anesthesia* 24(2): 103–10.

#### Original references

Catling S, Joels L. 2005. Cell salvage in obstetrics: the time has come. *BJOG: An International Journal of Obstetrics and Gynaecology* 112(2): 131–2.

National Institute for Health and Clinical Excellence. 2005. *Intraoperative Blood Cell Salvage in Obstetrics.* London: National Institute for Health and Clinical Excellence. URL: <http://guidance.nice.org.uk/IPG144/Guidance/pdf/English> (accessed 6 May 2013).

Royal College of Obstetricians and Gynaecologists. 2007. Blood transfusions in obstetrics. *Green-top Guideline No. 47.* Amended July 2008.URL: <http://www.rcog.org.uk/files/rcog-corp/uploaded-files/GT47BloodTransfusions1207amended.pdf> (accessed 6 May 2013).

Waters JH, Biscotti C, Potter PS, et al. 2000. Amniotic fluid removal during cell salvage in the cesarean section patient. *Anaesthesiology* 92(6): 1531–6.

### General

#### New references

Allard S, Green L, Hunt BJ. 2014. How we manage the haematological aspects of major obstetric haemorrhage. *British Journal of Haematology* 164(2): 177–88.

Cortet M, Maucort-Boulch D, Deneux-Tharaux C, et al. 2015. Severity of post-partum hemorrhage after vaginal delivery is not predictable from clinical variables available at the time post-partum hemorrhage is diagnosed. *Journal of Obstetrics and Gynaecology Research* 41(2): 199–206.

Girard T, Mörtl M, Schlembach D, et al. 2014. New approaches to obstetric hemorrhage: the postpartum hemorrhage consensus algorithm. *Current Opinion in Anaesthesiology* 27(3): 267–74.

Holm C, Thomsen LL, Norgaard A, et al. 2017. Single‐dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study. *Vox Sanguinis* 112: 122–31.

Howard TF, Grobman, WA. 2015. The relationship between timing of postpartum hemorrhage interventions and adverse outcomes. *American Journal of Obstetrics and Gynecology* 213(2): 239.e1–3.

Likis FE, Sathe NA, Morgans AK, et al. 2015. *Management of Postpartum Hemorrhage*. Comparative Effectiveness Review 151. Rockville, MD: Agency for Healthcare Research and Quality.

Mavrides E, Allard S, Chandraharan E, et al. 2017. Prevention and management of postpartum haemorrhage. *BJOG: An International Journal of Obstetrics & Gynaecology* 124(5): e106–e149.

Milman N. 2011. Postpartum anemia I: definition, prevalence, causes, and consequences. *Annals of Hematology* 90(11): 1247.

Nyfløt LT, Sandven I, Stray-Pedersen B, et al. 2017. Risk factors for severe postpartum hemorrhage: a case-control study. *BMC Pregnancy and Childbirth* 17: 17. DOI: 10.1186/s12884-016-1217-0 (accessed 5 February 2022).

Pacheco LD, Saade GR, Costantine MM, et al. 2016. An update on the use of massive transfusion protocols in obstetrics. *American Journal of Obstetrics and Gynecology* 214(3): 340–4.

Rani PR, Begum J. 2017. Recent advances in the management of major postpartum haemorrhage: a review. *Journal of Clinical and Diagnostic Research* 11(2): QE01–QE05.

Sheldon WR, Blum J, Vogel JP, et al. 2014. Postpartum haemorrhage management, risks, and maternal outcomes: findings from the World Health Organization Multicountry Survey on Maternal and Newborn Health. *BJOG: An international journal of obstetrics and gynaecology* 121(Suppl 1): 5–13.

Shields LE, Wiesner S, Fulton J, et al. 2015. Comprehensive maternal hemorrhage protocols reduce the use of blood products and improve patient safety. *American Journal of Obstetrics and Gynecology* 212(3): 272–80.

Stolp I, Smit M, Luxemburg S, et al. 2015. Ambulance transfer in case of postpartum hemorrhage after birth in primary midwifery care in the Netherlands: a prospective cohort study. *Birth* 42(3): 227–34.

Van de Velde M, Diez C, Varon AJ. 2015. Obstetric hemorrhage. *Current Opinion in Anaesthesiology* 28(2): 186–90.

#### Original references

Ahonen J, Stefanovic V, Lassila R. 2010. Management of post-partum haemorrhage. *Acta Anaesthesiologica Scandinavica* 54(10): 1164–78.

Centre for Maternal and Child Enquiries. 2011. ‘Top ten’ recommendations. Saving mothers’ lives: Reviewing maternal deaths to make motherhood safer: 2006–2008. *BJOG: An International Journal of Obstetrics and Gynaecology* 118(S1): 10–17. URL: <http://onlinelibrary.wiley.com/doi/10.1111/j.1471-0528.2010.02847.x/pdf> (accessed 22 September 2013).

Chavan R, Latoo M. 2013. Recent advances in the management of major obstetric haemorrhage. *British Journal of Medical Practitioners* 6(1): a604. URL: <http://www.bjmp.org/content/recent-advances-management-major-obstetric-haemorrhage> (accessed 3 September 2013).

Homer C, Clements V, McDonnell N, et al. 2009. Maternal mortality: what can we learn from stories of postpartum haemorrhage? *Women and Birth* 22(3): 97–104.

Mousa HA, Alfirevic Z. Treatment for primary postpartum haemorrhage. *Cochrane Database Syst Rev* 2009,Issue 1, Art. No. CD003249. DOI: 10.1002/14651858.CD003249.pub2 (accessed 1 July 2013).

Queensland Maternity and Neonatal Clinical Guidelines Program. 2012. *Queensland Maternity and Neonatal Clinical Guideline: Supplement:* *Primary postpartum haemorrhage.* URL: <http://www.health.qld.gov.au/qcg/documents/s_pph.pdf> (accessed 1 July 2013).

Royal College of Obstetricians and Gynaecologists. 2009. Prevention and management of postpartum haemorrhage. *Green-top Guideline No. 52.* Minor revisions November 2009 and April 2011.URL: <http://www.rcog.org.uk/files/rcog-corp/GT52PostpartumHaemorrhage0411.pdf> (accessed 1 July 2013).

Sobieszczyk S, Breborowicz G. 2004. Management recommendations for postpartum haemorrhage. *Archives of* *Perinatal Medicine* 10(4): 1–4.

Varatharajan L, Chandraharan E, Sutton J, et al. 2011. Outcome of the management of massive postpartum hemorrhage using the algorithm ‘HEMOSTASIS’. *International Journal of Gynaecology and Obstetrics* 113(2): 152–4.

### Training

#### New references

Egenberg S, Oian P, Eggebo TM, et al. 2016. Changes in self-efficacy, collective efficacy and patient outcome following interprofessional simulation training on postpartum haemorrhage. *Journal of Clinical Nursing* 26(19–20): 3174–87.

Lutgendorf MA, Spalding C, Drake E, et al. 2017. Multidisciplinary in situ simulation-based training as a postpartum hemorrhage quality improvement project. *Military Medicine* 182(3): e1762–e1766.

Marshall NE, Vanderhoeven J, Eden KB, et al. 2015. Impact of simulation and team training on postpartum hemorrhage management in non-academic centers. *Journal of Maternal-Fetal & Neonatal Medicine* 28(5): 495–9.

Shoushtarian M, Barnett M, McMahon F, et al. 2014. Impact of introducing Practical Obstetric Multi-Professional Training (PROMPT) into maternity units in Victoria, Australia. *BJOG: An International Journal of Obstetrics & Gynaecology* 121(13): 1710–8.

### Women’s experience

#### New references

Dunning T, Harris JM, Sandall J. 2016. Women and their birth partners’ experiences following a primary postpartum haemorrhage: a qualitative study. *BMC Pregnancy and Childbirth* 16: 80.

Eckerdal P, Kollia N, Löfblad J, et al. 2016. Delineating the association between heavy postpartum haemorrhage and postpartum depression. *PLOS ONE* 11(1): 1.

Elmir R. 2014. Finding meaning in life following emergency postpartum hysterectomy: what doesn’t kill us makes us stronger. *Journal of Midwifery & Women’s Health* 59(5): 510–5.

Elmir R, Schmied V, Jackson D, et al. 2012. Between life and death: women’s experiences of coming close to death, and surviving a severe postpartum haemorrhage and emergency hysterectomy. *Midwifery* 28(2): 228–35.

Elmir R, Schmied V, Wilkes L, et al. 2012. Separation, failure and temporary relinquishment: women’s experiences of early mothering in the context of emergency hysterectomy. *Journal of Clinical Nursing* 21(7–8): 1119–27.

Snowdon C, Elbourne D, Forsey M, et al. 2012. Information-hungry and disempowered: a qualitative study of women and their partners’ experiences of severe postpartum haemorrhage. *Midwifery* 28(6): 791–9.

1. In: Waitangi Tribunal. 2019. *Hauora: Report on Stage One of the Health Services and Outcomes Kaupapa Inquiry.* Wellington: Waitangi Tribunal. URL: <https://forms.justice.govt.nz/search/Documents/WT/wt_DOC_152801817/Hauora%20W.pdf> (accessed 2 February 2022). [↑](#footnote-ref-1)
2. See Ministry of Health’s Te Tiriti o Waitangi Framework for the Ministry’s four goals, each expressed in terms of mana. URL: <https://www.health.govt.nz/system/files/documents/pages/whakamaua-tiriti-o-waitangi-framework-a3-aug20.pdf> (accessed 2 February 2022). [↑](#footnote-ref-2)
3. Ministry of Health. 2019. *Achieving Equity*. URL: <https://www.health.govt.nz/about-ministry/what-we-do/work-programme-2019-20/achieving-equity> (accessed 2 February 2022). [↑](#footnote-ref-3)
4. Toi Te Ora Public Health. 2021. *Determinants of Health and Health Equity*. URL: <https://toiteora.govt.nz/public/determinants-of-health-and-health-equity/> (accessed 2 February 2022). [↑](#footnote-ref-4)
5. Ministry of Health. 2015. A framework for health literacy. URL: <https://www.health.govt.nz/publication/framework-health-literacy> (accessed 2 February 2022). [↑](#footnote-ref-5)
6. Te Tiriti o Waitangi framework as set out in: Ministry of Health. 2020. *Whakamaua: Māori Health Action Plan 2020–2025*. Wellington: Ministry of Health. [↑](#footnote-ref-6)